Dozens march in honor of International Trans Day of Visibility
EVANSVILLE, Ind. (WEHT) — Several groups of people marched from the Four Freedoms Monument to the Civic Center ahead of the city council meeting, celebrating the International Trans Day of Visibility.
In Indiana, certain laws ban gender-affirming care for transgender youth including hormone therapy, puberty blockers and surgeries.
Charlotte Morrison helped organize the march. She also helped draft a resolution that, if passed, would establish the city as a safe haven for gender-affirming care. She hopes the demonstration will help city leaders realize more work needs to be done.
'It's for anybody who receives gender affirming care,' says Morrison. 'It is not just under 18 or over 18, it is anyone who receives it in the city.'
15 people spoke in favor of the resolution, saying it is needed to help protect the transgender community. But, not everyone agrees.
City council members are looking at the resolution and plan to discuss it in future meetings.
Eyewitness News. Everywhere you are.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Jim Cramer on Cardinal Health: 'I am a Believer'
Cardinal Health, Inc. (NYSE:CAH) is one of the 11 stocks on Jim Cramer's radar. Calling Cardinal Health, Inc.'s (NYSE:CAH) upcoming Investor Day a possible needle mover, Cramer said: 'Now, Thursday brings some analyst meetings that could move the needle. Cardinal Health, we've had them on a couple of times, tells a terrific story about how it's much more than a drug middleman. And I believe, I am a believer.' A senior physician in a modern healthcare institution administering medication to a patient. Cardinal Health (NYSE:CAH) provides medical products and services used in various care settings. The company delivers pharmaceuticals, equipment, and support tools while managing distribution, logistics, and pharmacy operations through healthcare-focused technology. On May 14, Cramer extensively commented on the company as he said: 'These stocks, namely Cardinal Health, Cencora, and McKesson, are seemingly perpetual residents on the new high list. Over the long haul, they're some of the best performers out there, and they've done great this year, as is pretty much always the case. And yet, doesn't it always feel like the drug distributors are just one bad day away from falling apart… Let's not forget that the drug distributors are making fortunes right now. Cardinal Health turned in an excellent set of numbers two weeks ago with double-digit earnings growth. Management put through a big boost in their full-year earnings forecast. Cardinal stock jumped 3% in response, climbing from $141 to $145, and it kept running for really a week after that, eventually setting at an all-time high of $154 just last Thursday. What a fabulous move… While we acknowledge the potential of CAH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
an hour ago
- Yahoo
Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials
Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. A close-up of a person's hand holding a bottle of pharmaceuticals. The medication is being studied as a potential treatment for hyperlipidemia, a condition marked by high levels of fat in the bloodstream. According to the company, enlicitide led to significant reductions in LDL-C, or "bad" cholesterol, in patients with existing heart disease or those at risk of developing it. Merck & Co., Inc. (NYSE:MRK) is a global healthcare organization focused on providing innovative health solutions through its medicines, vaccines, biologic therapies, and animal health products. The stock has surged by over 1% in the past month. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Merck's Cholesterol Medication Achieves Primary Endpoint in Two Trials
Merck & Co., Inc. (NYSE:MRK) is one of the best Dow stocks to invest in. On June 9, the company announced that its drug, enlicitide decanoate, achieved its primary goal of lowering a specific type of cholesterol in two late-stage clinical trials. A close-up of a person's hand holding a bottle of pharmaceuticals. The medication is being studied as a potential treatment for hyperlipidemia, a condition marked by high levels of fat in the bloodstream. According to the company, enlicitide led to significant reductions in LDL-C, or "bad" cholesterol, in patients with existing heart disease or those at risk of developing it. Merck & Co., Inc. (NYSE:MRK) is a global healthcare organization focused on providing innovative health solutions through its medicines, vaccines, biologic therapies, and animal health products. The stock has surged by over 1% in the past month. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
